Von Willebrand Disease Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 6.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Von Willebrand Disease Treatment Market Analysis
The Von Willebrand Disease Treatment Market is expected to register a CAGR of 6.5% during the forecast period.
Factors such as a rise in patient assistance programs and increasing healthcare expenditure worldwide are expected to fuel the market's growth during the forecast period.
The incidence and prevalence of VWD disease are increasing globally and creating new opportunities for developing new drugs, therapies, and treatments in the market. For instance, according to the CDC in May 2024, Von Willebrand disease (VWD) affects approximately 1% of the general population, with men and women equally susceptible. However, due to the heightened bleeding it triggers, women often exhibit more pronounced VWD symptoms, especially during menstruation, pregnancy, and post-childbirth. From 2012 to 2023, over 33,456 individuals, encompassing men, women, and children, sought treatment for VWD at hemophilia treatment centers. Notably, nearly two-thirds of these patients were women and girls. Thus, the high burden of VWD is expected to increase demand for novel therapies, including novel clotting factors and other medications entering the market, expanding the treatment options available, thereby boosting market growth.
In addition, as per a research study published in the Journal of Blood Medicine in March 2023, approximately 0.6-1.3% of the general population was affected by VWD, and the prevalence of symptomatic VWD was approximately 10 per 100,000 during the study period of the research. This growing disease burden is attracting the focus of government bodies and market players toward investments and the development of innovative drugs, contributing to market growth. Thus, the market is expected to grow over the forecast period due to the abovementioned factors.
The strategic initiatives taken by market players, such as product launches and mergers and acquisitions, are expected to contribute to market growth over the forecast period. For instance, in April 2022, Octapharma, a key player in the healthcare industry, secured the prestigious title of Gold Sponsor for the World Federation of Haemophilia (WFH) 2022 World Congress, scheduled from May 8 to 11, 2022. At the event, Octapharma announced plans to shed light on the critical unmet needs faced by individuals grappling with Von Willebrand disease (VWD) through a live symposium. Similarly, in January 2022, Takeda secured FDA approval in the United States for VONVENDI, a recombinant Von Willebrand factor, for patients with severe type 3 Von Willebrand disease, specifically for routine prophylaxis alongside on-demand therapy.
Thus, all the aforementioned factors, such as the growing burden of VWD and strategic initiatives taken by market players, are expected to boost market growth over the forecast period. However, the need for more awareness and the high cost of treatment are the factors hindering market growth.
Von Willebrand Disease Treatment Market Trends
Replacement Therapy Segment Expected to Register Significant Growth
The replacement therapy segment is anticipated to witness significant growth. Replacement therapy is referred to as the therapy involving the supply of a substance (such as a hormone or nutrient) lacking in or lost from the body. The replacement therapy segment is growing and is expected to continue growing over the forecast period.
Analysis of several studies and articles shows that treatment of VWD is primarily done with replacement therapies such as vWF and factor VIII plasma concentrates and recombinant vWF, which show effective results among patients. Hence, research is ongoing to evaluate the safety and efficacy of replacement therapies for VWD.
For instance, as per a research study published in the Blood Transfusion Journal in April 2022, a clinical trial program was conducted with a replacement therapy in pediatric patients treated with Wilfactin for up to 4.2 years. In 90.3% of episodes, good hemostatic efficacy was achieved, and a safe and effective treatment was provided in patients aged below six years with severe VWD. Thus, such research demonstrating positive results generates demand for the availability of replacement therapies in the market and is expected to boost the segment's growth.
The increasing number of product approvals is one of the major factors expected to fuel the segment's growth over the forecast period. Several market players are engaged in obtaining approvals for replacement therapies for the treatment of VWD. For instance, in January 2022, the United States Food & Drug Administration (FDA) approved Takeda Pharmaceutical Company Limited's VONVENDI [Von Willebrand factor (Recombinant)] for routine prophylaxis. This approval is designed to reduce the frequency of bleeding episodes in patients with severe type 3 Von Willebrand disease (VWD) who currently rely on on-demand therapy. VONVENDI is notable as the only recombinant Von Willebrand factor (VWF) replacement therapy available. It marks the FDA's first endorsement for routine prophylactic use, specifically targeting the reduction of bleeding episodes in patients with severe type 3 VWD.
Thus, the significant efficacy of replacement therapy in VWD and the increasing number of product launches are expected to contribute to the segment’s growth over the forecast period.
North America Expected to Hold a Significant Market Share Over the Forecast Period
North America holds a significant market share, and this trend is expected to continue during the forecast period. The factors attributing to the high market share of North America are the consistent focus on cost-effective and innovative drugs and the increasing prevalence of the disease across the regional countries.
The United States, among other regional countries, has shown growth in the market studied. The major factors contributing to the market growth in the United States are the rising incidence of Von Willebrand disease, the growing number of strategic initiatives, and the increasing number of patient assistance programs. For instance, as per the 2023 data update by the National Hemophilia Foundation, 1 in 100 people in the United States have been found to have VWD every year. Therefore, this burden of the disease is creating a significant demand for the availability of innovative treatments in the country, contributing to the regional market’s growth.
Several initiatives are being undertaken to raise awareness, which, along with VWD's product approvals, are fueling market growth. For instance, in April 2024, Octapharma USA Inc. received orphan drug exclusivity from the US FDA for its product, wilate. Wilate is a lyophilized powder for intravenous injection designed for routine prophylaxis. It aims to lessen the occurrence of bleeding episodes in individuals aged six and above diagnosed with Von Willebrand disease (VWD).
Thus, the regional market is expected to grow significantly during the forecast period due to the factors mentioned above.
Von Willebrand Disease Treatment Industry Overview
The Von Willebrand disease treatment market is semi-consolidated, with the presence of many global players. The market players have adopted several strategies, such as product launches, mergers, and acquisitions, to stay competitive in the market. The most prominent players in the market are Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical, and Takeda.
Von Willebrand Disease Treatment Market Leaders
-
CSL Behring
-
Grifols, S.A.
-
Takeda Pharmaceutical Company Ltd
-
Octapharma AG
-
Bio Products Laboratory Ltd.
*Disclaimer: Major Players sorted in no particular order
Von Willebrand Disease Treatment Market News
- June 2024: Star Therapeutics unveiled clinical findings from VIVID 1, a Phase 1 study (VGA039 Investigation in Von Willebrand Disease), showcasing VGA039's potential as a groundbreaking hemostatic treatment. This study, conducted on healthy volunteers, positioned VGA039 not only as a versatile solution for various bleeding disorders but also as a pioneering subcutaneous treatment for Von Willebrand disease (VWD).
- February 2023: The USFDA approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is a novel Von Willebrand Factor (VWF) independent recombinant factor VIII therapy designed to extend protection from bleeds with once-weekly prophylactic dosing for adults and children with hemophilia A.
Von Willebrand Disease Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Patient Assistance Programs
4.2.2 Growing Healthcare Expenditure
4.3 Market Restraints
4.3.1 Lack of Awareness
4.3.2 High Costs of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Disease Type
5.1.1 Type 1
5.1.2 Type 2
5.1.3 Type 3
5.1.4 Acquired VWD
5.2 By Treatment Type
5.2.1 Desmopressin
5.2.2 Replacement Therapies
5.2.3 Clot-stabilizing Medications
5.2.4 Other Treatment Types
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Injection
5.3.3 Other Routes of Administration
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 CSL Behring
6.1.2 Ferring Pharmaceuticals
6.1.3 Grifols SA
6.1.4 Octapharma AG
6.1.5 Pfizer Inc.
6.1.6 Sanofi SA
6.1.7 Takeda Pharmaceutical Company Ltd
6.1.8 Bio Products Laboratory Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Von Willebrand Disease Treatment Industry Segmentation
As per the scope of the report, Von Willebrand disease (VWD) is a genetic disorder that delays the process of blood clotting. It is generally caused by a missing or defective Von Willebrand factor (VWF), a clotting protein.
The Von Willebrand disease treatment market is segmented by disease type, treatment type, route of administration, and geography. By disease type, the market is segmented into type 1, type 2, type 3, and acquired VMD. By treatment type, the market is segmented into desmopressin, replacement therapies, clot-stabilizing medication, and other treatment types. By route of administration, the market is segmented into oral, injection, and other routes of administration. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in value (USD) for the above segments.
| By Disease Type | |
| Type 1 | |
| Type 2 | |
| Type 3 | |
| Acquired VWD |
| By Treatment Type | |
| Desmopressin | |
| Replacement Therapies | |
| Clot-stabilizing Medications | |
| Other Treatment Types |
| By Route of Administration | |
| Oral | |
| Injection | |
| Other Routes of Administration |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Von Willebrand Disease Treatment Market Research FAQs
What is the current Von Willebrand Disease Treatment Market size?
The Von Willebrand Disease Treatment Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)
Who are the key players in Von Willebrand Disease Treatment Market?
CSL Behring, Grifols, S.A., Takeda Pharmaceutical Company Ltd, Octapharma AG and Bio Products Laboratory Ltd. are the major companies operating in the Von Willebrand Disease Treatment Market.
Which is the fastest growing region in Von Willebrand Disease Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Von Willebrand Disease Treatment Market?
In 2024, the North America accounts for the largest market share in Von Willebrand Disease Treatment Market.
What years does this Von Willebrand Disease Treatment Market cover?
The report covers the Von Willebrand Disease Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Von Willebrand Disease Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Von Willebrand Disease Treatment Industry Report
Statistics for the 2024 Von Willebrand Disease Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Von Willebrand Disease Treatment analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
